Submit justification: CDSCO panel tells Hetero for FDC Lacosamide, Brivaracetam
In line with the drug maker Hetero Pharma's proposal for the fixed-dose combination Lacosamide plus Brivaracetam, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit the justification in respect to the combination drug to the CDSCO for further review by the committee.
This came after the drug maker Hetero Pharma presented its proposal along with bioequivalence (BE) and Phase III clinical trial protocol before the committee.
For more details, check out the full story on the link below:
Submit Justification: CDSCO Panel Tells Hetero For FDC Lacosamide, Brivaracetam
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd